Quick Takeaways
- Paradigm Biocapital Advisors LP filed SCHEDULE 13G/A for LENZ Therapeutics, Inc. Common Stock, $0.00001 par value per share (LENZ).
- Disclosed ownership: 3.8%.
- Date of event: 30 Sep 2025.
Paradigm Biocapital Advisors LP - 30 Sep 2025 SCHEDULE 13G/A Report for LENZ Therapeutics, Inc. Common Stock, $0.00001 par value per share (LENZ)
- Filing Manager
- Paradigm Biocapital Advisors LP
- Reporting Manager
- Paradigm BioCapital Advisors LP
- Symbol
- LENZ
- Shares outstanding
- 28,248,974 shares
- Disclosed Ownership
- 1,073,461 shares
- Ownership
- 3.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 16:32:28 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 27 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Paradigm Biocapital Advisors LP disclosed 3.8% ownership in LENZ Therapeutics, Inc. Common Stock, $0.00001 par value per share (LENZ) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 27 Mar 2025.
- Current filing was accepted on 14 Nov 2025, 16:32.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 3.8% | 1,073,461 | 1,073,461 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Paradigm BioCapital Advisors GP LLC | 3.8% | 1,073,461 | 1,073,461 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Senai Asefaw, M.D. | 3.8% | 1,073,461 | 1,073,461 | 0 | /s/ Senai Asefaw, M.D. | N/A | |
| Paradigm BioCapital International Fund Ltd. | 3.3% | 946,447 | 946,447 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory |